Medicenna Therapeutics (TSE:MDNA) Sets New 12-Month Low – Time to Sell?

Medicenna Therapeutics Corp. (TSE:MDNA)’s stock price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$0.41 and last traded at C$0.41, with a volume of 65291 shares trading hands. The stock had previously closed at C$0.41.

Medicenna Therapeutics Trading Up 2.4%

The company has a current ratio of 2.68, a quick ratio of 4.65 and a debt-to-equity ratio of 3.30. The firm has a 50-day moving average of C$0.51 and a 200 day moving average of C$0.75. The company has a market cap of C$35.04 million, a P/E ratio of -2.80 and a beta of 2.89.

Medicenna Therapeutics (TSE:MDNA) last released its earnings results on Thursday, April 30th. The company reported C($0.06) EPS for the quarter. Medicenna Therapeutics had a negative return on equity of 103.51% and a negative net margin of 533,640.00%. On average, analysts predict that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current fiscal year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.